SCHEMBL20914080

SCHEMBL20914080

CSc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.32

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.31
▸ RXFP1 Q9HBX9 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ PPARG P37231 1/20 0.31
▸ NCOR2 Q9Y618 1/20 0.31
▸ PDGFRA P16234 1/20 0.31
▸ MAPK8 P45983 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ CLK4 Q9HAZ1 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ GRM5 P41594 1/20 0.30
▸ MAT2A P31153 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913968 0.88 KDM4E (0.34) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20837038 0.88 ADORA2A (0.34) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20913931 0.86 KMT2A (0.35) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914299 0.86 CYP1A2 (0.35) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914077 0.86 TNKS (0.37) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20837037 0.85 P2RY6 (0.37) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914337 0.84 POLB (0.37) KMT2AMEN1ALDH1A1KDM4EL3MBTL1
SCHEMBL20914221 0.83 HTR3A (0.31) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20913982 0.81 MAT2A (0.34) KMT2AMEN1CYP1A2CYP2C9PKM
SCHEMBL20914308 0.81 MAT2A (0.34) KMT2AMEN1CYP1A2CYP2C9PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
CN-111212839-A Pyrazolopyrimidinone compounds and uses thereof 艾杜罗生物科技公司 2020-05-29 — — CN disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KMT2A 3490/4885MEN1 2785/4885CYP1A2 1015/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KMT2A 3490/4885MEN1 2785/4885CYP1A2 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback